Known targets — ChEMBL curated mechanism
ADORA1ADORA2AADORA2BADORA3PDE3APDE3BPDE4APDE4BPDE4CPDE4D
The experimentally established mechanism targets of Isoleucine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.46 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.43 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.43 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.43 |
| ▸ | DPP4 | P27487 | 11/20 | 0.43 |
| ▸ | DPP8 | Q6V1X1 | 7/20 | 0.43 |
| ▸ | DPP9 | Q86TI2 | 7/20 | 0.43 |
| ▸ | DPP7 | Q9UHL4 | 6/20 | 0.39 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.38 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.38 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Isoleucine SCHEMBL1537377 | 1.00 | SLC7A5 (0.46) | SLC7A5GLRA1SLC6A9OR51E2DPP4 | |
| Isoleucine SCHEMBL1537379 | 1.00 | SLC7A5 (0.46) | SLC7A5GLRA1SLC6A9OR51E2DPP4 | |
| Isoleucine SCHEMBL94554 | 1.00 | SLC7A5 (0.46) | SLC7A5GLRA1SLC6A9OR51E2DPP4 | |
| Isoleucine SCHEMBL8492488 | 1.00 | SLC7A5 (0.46) | SLC7A5GLRA1SLC6A9OR51E2DPP4 | |
| Isoleucine SCHEMBL3046356 | 1.00 | SLC7A5 (0.46) | SLC7A5GLRA1SLC6A9OR51E2DPP4 | |
| Isoleucine SCHEMBL1537299 | 1.00 | SLC7A5 (0.46) | SLC7A5GLRA1SLC6A9OR51E2DPP4 | |
| Isoleucine SCHEMBL1675494 | 1.00 | SLC7A5 (0.46) | SLC7A5GLRA1SLC6A9OR51E2DPP4 | |
| Isoleucine SCHEMBL11168084 | 0.96 | SLC7A5 (0.43) | SLC7A5GLRA1SLC6A9OR51E2DPP4 | |
| Isoleucine SCHEMBL3057441 | 0.96 | SLC7A5 (0.43) | SLC7A5GLRA1SLC6A9OR51E2DPP4 | |
| Isoleucine SCHEMBL2547350 | 0.96 | SLC7A5 (0.43) | SLC7A5GLRA1SLC6A9OR51E2DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021062231-A2 | CANNABINOID PRODRUG COMPOUNDS | FIRSTLIGHT PHARMACEUTICALS LLC (US) | 2021-04-01 | — | — | WO | claimed |
| CN-109477071-A | The 3D printing of cellularised bracket | 牛津大学创新有限公司 | 2019-03-15 | — | — | CN | claimed |
| CN-1649899-A | Connective tissue stimulating peptides | MILLENIUM BIOLOGIX INC (CA) | 2005-08-03 | — | — | CN | claimed |
| US-11980602-B2 | Cannabinoid prodrug compounds | FIRSTLIGHT PHARMACEUTICALS LLC (US) | 2024-05-14 | — | — | US | disclosed |
| CN-109922825-B | Vaccine for resisting porcine parvovirus and porcine reproductive and respiratory syndrome virus and preparation method thereof | 勃林格殷格翰动物保健有限公司 | 2024-01-12 | — | — | CN | disclosed |
| US-11730806-B2 | Methods of manufacturing an immunogenic composition comprising a recombinant protein | BOEHRINGER INGELHEIM VETMEDICA GMBH | 2023-08-22 | — | — | US | disclosed |
| EP-3534939-B1 | VACCINE AGAINST PORCINE PARVOVIRUS AND PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME VIRUS AND METHODS OF PRODUCTION THEREOF | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2023-02-22 | — | — | EP | disclosed |
| US-20220220430-A1 | METHODS OF MONITORING CELL CULTURE MEDIA | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-07-14 | — | — | US | disclosed |
| US-20220211656-A1 | CANNABINOID PRODRUG COMPOUNDS | FIRSTLIGHT PHARMACEUTICALS LLC | 2022-07-07 | — | — | US | disclosed |
| EP-3973274-A1 | METHODS OF MONITORING CELL CULTURE MEDIA | Bristol-Myers Squibb Company (US) | 2022-03-30 | — | — | EP | disclosed |
| WO-2021062231-A2 | CANNABINOID PRODRUG COMPOUNDS | FIRSTLIGHT PHARMACEUTICALS LLC (US) | 2021-04-01 | — | — | WO | disclosed |
| EP-1756047-A1 | PROCESS FOR PREPARING AMINO ACIDS USING THE AMIDOCARBONYLATION REACTION (1) | Degussa GmbH (DE) | 2007-02-28 | — | — | EP | disclosed |
| WO-2005121079-A1 | PROCESS FOR PREPARING AMINO ACIDS USING THE AMIDOCARBONYLATION REACTION (1) | DEGUSSA AG (DE) | 2005-12-22 | — | — | WO | disclosed |
| WO-2005121068-A1 | PROCESS FOR PREPARING AMINO ACIDS USING THE AMIDOCARBONYLATION REACTION | DEGUSSA AG (DE) | 2005-12-22 | — | — | WO | disclosed |
| CN-1649899-A | Connective tissue stimulating peptides | MILLENIUM BIOLOGIX INC (CA) | 2005-08-03 | — | — | CN | disclosed |
| US-20050032726-A1 | Protein kinase (PK); for increasing the susceptibility of a cell to DNA-damaging agents via hybridization of nucleic acids encoding DNA dependent protein kinases, preventing gene expression; genetic engineering | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2005-02-10 | — | — | US | disclosed |
| EP-1083881-B1 | LIPOSOME COMPOSITIONs containing a quinolone derivative AND their use as antibacterial agents | ALZA CORP (US) | 2004-08-25 | — | — | EP | disclosed |
| EP-1083881-A2 | LIPOSOME COMPOSITION AND METHOD FOR ADMINISTERING A QUINOLONE | ALZA Corporation (US) | 2001-03-21 | — | — | EP | disclosed |
| US-5972379-A | LIPOSOMES HAVING A SURFACE COATING OF HYDROPHILIC POLYMER CHAINS AND AN ENTRAPPED CIPROFLOXACIN-AMINO ACID CONJUGATE, USEFUL FOR TREATING THE BACTERIAL INFECTIONS | SEQUUS PHARMACEUTICALS, INC. (US) | 1999-10-26 | — | — | US | disclosed |
| WO-1999051202-A2 | QUINOLONE CONTAINING LIPOSOMES AND THEIR USE AS ANTIBACTERIAL AGENTS | SEQUUS PHARMACEUTICALS, INC. (US) | 1999-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220211656-A1 | CANNABINOID PRODRUG COMPOUNDS | CNR2, CNR1, FAAH | SLC7A5 4029/4885GLRA1 2621/4885SLC6A9 1624/4885 |
| US-11980602-B2 | Cannabinoid prodrug compounds | CNR2, CNR1, FAAH | SLC7A5 4029/4885GLRA1 2621/4885SLC6A9 1624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.